Medical device companies have been under fire recently. Pricing pressures, a down economy, cash-strapped hospitals, and a competitive landscape have sent sales reeling at several major firms. Boston Scientific (NYSE:BSX) has been hit especially hard, with its cardiac rhythm management (CRM) and interventional cardiology businesses seeing revenues fall across the board.

This company won't sit by as its outlook wanes, however. Boston's Watchman atrial fibrillation device has been turned down once by the Food and Drug Administration already, but promising new trial data has breathed life back into this new technology. With the atrial fibrillation industry on the rise, is this just what Boston needed to save its cardiovascular business' future? Motley Fool contributor Dan Carroll and health care analyst Max Macaluso discuss that and more below.